Abstract

Medical care is predicated on 'do no harm', yet the urgency to find drugs and vaccines to treat or prevent COVID-19 has led to an extraordinary effort to develop and test new therapies. Whilst this is an essential cornerstone of a united global response to the COVID-19 pandemic, the absolute requirements for meticulous efficacy and safety data remain. This is especially pertinent to the needs of pregnant women; a group traditionally poorly represented in drug trials, yet a group at heightened risk of unintended adverse materno-fetal consequences due to the unique physiology of pregnancy and the life course implications of fetal or neonatal drug exposure. However, due to the complexities of drug trial participation when pregnant (be they vaccines or therapeutics for acute disease), many clinical drug trials will exclude them. Clinicians must determine the best course of drug treatment with a dearth of evidence from either clinical or preclinical studies, where at least in the short term they may be more focused on the outcome of the mother than of her offspring.

Highlights

  • Since the beginning of 2020, when most of us had not heard of COVID-19, as of 8 October 2020,1 there have been over 36 million cases of SARS-CoV-2 and 1 million deaths from COVID-19 globally

  • The principles of developmental origins of health and disease (DOHaD) highlight the importance of taking a life course approach and understanding the mechanisms linking exposures during pregnancy on offspring health in infancy, childhood, adulthood and old age,[63,64,65] and this must be considered in the case of COVID-19

  • Treatment of COVID-19 represents a profound challenge to physicians across the globe

Read more

Summary

Origins of Health and Disease harming her baby?

Berry[2], Pravin Hissaria[3], Jack R.T. Darby[1,4] and Janna L. Morrison[1,4]. Cite this article: Wiese MD, Berry MJ, Hissaria P, Darby JRT, and Morrison JL. COVID-19: can we treat the mother without harming her baby? Journal of Developmental Origins of Health and Disease doi: 10.1017/ S2040174420001403 COVID-19: can we treat the mother without harming her baby? Journal of Developmental Origins of Health and Disease doi: 10.1017/ S2040174420001403

Background
Drug safety in pregnancy
Protease inhibitors
Pregnancy outcomes
Birth outcomes
Monoclonal antibodies
Childhood outcomes No data
Findings
Concluding remarks
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.